Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70112 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Weiping Jia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Ce…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Innogen Pharmaceutical Co. Ltd., Shanghai, China.
Abstract (Originalsprache)
Aims Efsubaglutide Alfa is a novel, long‐acting, once‐weekly GLP‐1 receptor agonist. In the pivotal phase 2b/3 SUPER2 trial, Efsubaglutide Alfa 3 mg plus metformin showed significant efficacy and favourable safety in patients with type 2 diabetes (T2D) inadequately controlled on metformin. This post‐hoc analysis evaluated the 1 mg dose. Materials and methods In phase 2b, patients with T2D on metformin were randomized (1:1:1) to once‐weekly Efsubaglutide Alfa 1 mg, 3 mg, or placebo for 12 weeks. After interim analysis, 3 mg was selected as the phase 3 dose. However, 155 patients already randomized (the “overrun” cohort) completed 24 weeks of double‐blind treatment with 1 mg, then entered 28 weeks of open‐label 3 mg and 4 weeks of follow‐up. This analysis focused on the 1 mg cohort. The primary endpoint was change in HbA1c at week 24; secondary endpoints included fasting plasma glucose (FPG), body weight, HbA1c
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laborator…
- Innogen Pharmaceutical Technology Co., Ltd., Shanghai, China.
- Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai, China.
ORCID-Profile: Weiping Jia, Yuqian Bao, Qinghua Wang
Förderung
- Innogen Pharmaceutical Co. Ltd., Shanghai, China
Zitieren
APA
Jia, W., Jiang, F., Xu, Y., Li, Y., Bao, Y., & Wang, Q. (2025). Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70112
Vancouver
Jia W, Jiang F, Xu Y, Li Y, Bao Y, Wang Q. Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70112
BibTeX
@article{Jia2025,
author = {Jia, Weiping and Jiang, Fan and Xu, Yulong and Li, Yiming and Bao, Yuqian and Wang, Qinghua},
title = {Efficacy and safety of Efsubaglutide Alfa in “overrun” patients in the SUPER2 trial: A post‐hoc analysis for comprehensive evaluation},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70112}
}
EUVIMED